Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of in vitro human metabolism studies in drug development. An industrial perspective.

× No keyword cloud information.

12 in total

Review 1. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors: G R Wilkinson
Journal: J Pharmacokinet Biopharm Date: 1996-10

2. Automated QSPR through Competitive Workflow.

Authors: J Cartmell; S Enoch; D Krstajic; D E Leahy
Journal: J Comput Aided Mol Des Date: 2006-01-17 Impact factor: 3.686

Review 3. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors: Timothy W Harper; Patrick J Brassil
Journal: AAPS J Date: 2008-04-05 Impact factor: 4.009

4. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

Authors: C Prakash; A Kamel; D Cui; R D Whalen; J J Miceli; D Tweedie
Journal: Br J Clin Pharmacol Date: 2000 Impact factor: 4.335

5. A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.

Authors: Olga Trubetskoy; Bryan Marks; Thomas Zielinski; Mei-Fei Yueh; Judy Raucy
Journal: AAPS J Date: 2005-03-04 Impact factor: 4.009

6. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

Authors: Helen C Swaisland; Malcolm Ranson; Robert P Smith; Joanna Leadbetter; Alison Laight; David McKillop; Martin J Wild
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

7. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

Authors: H C Rawden; G O Kokwaro; S A Ward; G Edwards
Journal: Br J Clin Pharmacol Date: 2000-04 Impact factor: 4.335

Use of in vitro human metabolism studies in drug development. An industrial perspective.